In 1984, fluoroestradiol (FES) was first developed by researchers Michael J. Welch, PhD from Washington University at St. Louis and John Katzenellenbogen, PhD from Harvard University .

FES was the first PET probe for a receptor in cancer, and its development and clinical applications in breast cancer parallel the conceptual evolution of the whole field of receptor-binding radiotracers.